Apcotex Industries: Axis Direct is a buy on this specialty chemicals company, giving it an upside of 20% on a target price of Rs. 410. "For Q1FY22, Apcotex missed our top-line estimates but beat EBITDA and PAT estimates," analysts Suvarna Joshi and Darshita Shah write. "Industries like Paper & Paperboard (packaging), Tyre, Footwear, Auto, and Construction helped the company in recording strong growth in the current quarter." They think Apcotex is on track for longer term growth: "Along with the current strong demand, the diversification in the end-user industries that the company caters to will help it maintain the growth levels for the next 3- 5 years." PE Buy Sell Zone for Apcotex

Oberoi Realty: ICICI Securities is a buy on this realty company, with a target price of Rs. 830, a 23%+ upside. "Oberoi Realty is uniquely positioned in Mumbai's premium residential segment, and is moving towards a balanced mix of retail, commercial and hospitality assets," analysts Bhupendra Tiwary and Lokesh Kashikar write. "This will provide stability to slow-moving and volatile revenue streams." The analysts are expecting a rapid recovery in "malls, hotels and office assets." PE Buy/Sell Zone for Oberoi Realty

Shriram Transport Finance: Despite the pummelling the auto industry has received during the pandemic, Edelweiss is bullish on this transport finance company, giving it a 22%+ upside on a target price of Rs. 1700. "PAT was significantly lower than estimates due to higher-than-expected credit costs, but disbursements surprised positively, declining only 15% QoQ, well ahead of peers." analysts Jigar Jani and Raj Jha write. "We believe it is well placed to capture the revival in the CV cycle due to (a) it being the largest player in the CV financing space (b) lower-than-expected restructuring and (c) better than-expected asset quality." PE Buy/Sell Zone for STFC

Ajanta Pharma: Motilal Oswal sees an upside of 21%+ on a target price of Rs. 2780 for this pharma business. "AJP is on track to outperform in the Branded Generics segment across DF/Asia/Africa and build a product pipeline for the US market," analysts Tushar Manudhane and Bharat Hegde write. "Ajanta has completed its major capex to cater to growth for the next three years," they observe, "We remain positive on the company due to  a) new launches and market share gains in the key markets of the US/DF/Asia/Africa, b) the benefits of major capex (to accrue over the next 2–3 years), c) improved operating leverage." PE Buy/Sell Zone for Ajanta Pharma

Larsen & Toubro (L&T): Geojit BNP is bullish on this engineering conglomerate, giving it an upside of 20%+ on a target price of Rs. 1935. "Q1FY22 revenue grew 38.0% YoY, on solid order book coupled with large project executions and robust E&C growth amidst pandemic," analyst Sheen G writes, "High liquidity, improved leverage, prospective pipeline with better utilization and production is expected to continue in the near-term." PE Buy/Sell Zone for L&T